Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MTCO1P22 (MT-CO1 pseudogene 22) is a nuclear-encoded pseudogene, resulting from the retrotransposition or translocation of mitochondrial cytochrome c oxidase subunit I (MT-CO1) gene sequence into the nuclear genome. It is annotated as a non-protein-coding sequence and does not contribute to cytochrome c oxidase activity. Unlike its functional mitochondrial counterpart (MT-CO1), MTCO1P22 has no demonstrated biological function, clinical relevance, or drug interactions. Its existence is a remnant of genome evolution and serves as a genetic artifact rather than a molecular target. In summary, MTCO1P22 is a pseudogene and not a therapeutic target, with no known biological function, disease relevance, or drug interactions. Its annotations are correct and current, but its clinical and pharmacological relevance is null.
None (no mechanisms, since it's not a functional or druggable entity)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MT-CO1 pseudogene 22 (MTCO1P22).